| Acquired by | MacroGenics |
| Date | 7/08 |
| Category | BioTech |
| Phone | 650-624-2600 |
| Employees | |
| Founded | 1999 |
| TOTAL | $48.3M |
| FUNDING TOTAL | $48.3M |
| Series D, 10/05 Vulcan Capital Biogen Idec CIDC Consultants Mitsubishi UFJ Capital Bear Stearns Pequot Ventures Integra Ventures U.S. Venture Partners CMEA Ventures Hambrecht & Quist Capital Management Milepost Ventures Cogene Ventures | $48.3M |
Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.
